# Telmisartan in Respiratory Failure Due to COVID-19

> **NCT04510662** · PHASE2 · COMPLETED · sponsor: **Abraham Edgar Gracia-Ramos** · enrollment: 66 (actual)

## Conditions studied

- COVID-19
- Respiratory Insufficiency
- Telmisartan
- Respiratory Distress Syndrome, Adult

## Interventions

- **DRUG:** Telmisartan

## Key facts

- **NCT ID:** NCT04510662
- **Lead sponsor:** Abraham Edgar Gracia-Ramos
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-12
- **Primary completion:** 2021-05-15
- **Final completion:** 2021-05-25
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510662, "Telmisartan in Respiratory Failure Due to COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04510662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*